Pharsight

Drugs that contain Pemigatinib

1. Drug name - PEMAZYRE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9611267 INCYTE CORP Substituted tricyclic compounds as FGFR inhibitors
Jan, 2035

(12 years from now)

CN107383009A INCYTE CORP Substituted Tricyclic Compound As Fgfr Inhibitor
Jun, 2033

(10 years from now)

CN107652289A INCYTE CORP Substituted Tricyclic Compound As Fgfr Inhibitors
Jun, 2033

(10 years from now)

CN104507943A INCYTE CORP Substituted Tricyclic Compound As Fgfr Inhibitor
Jun, 2033

(10 years from now)

CN104507943B INCYTE CORP Substituted Tricyclic Compound As Fgfr Inhibitor
Jun, 2033

(10 years from now)

CN107383009B INCYTE CORP Substituted Tricyclic Compound As A Fgfr Inhibitor
Jun, 2033

(10 years from now)

CN107652289B INCYTE CORP Substituted Tricyclic Compounds As Fgfr Inhibitors
Jun, 2033

(10 years from now)

EP3495367B1 INCYTE CORP Substituted Tricyclic Compounds As Fgfr Inhibitors
Jun, 2033

(10 years from now)

EP3176170B1 INCYTE CORP Substituted Tricyclic Compounds As Fgfr Inhibitors
Jun, 2033

(10 years from now)

EP3495367A1 INCYTE CORP Substituted Tricyclic Compounds As Fgfr Inhibitors
Jun, 2033

(10 years from now)

EP3176170A1 INCYTE CORP Substituted Tricyclic Compounds As Fgfr Inhibitors
Jun, 2033

(10 years from now)

EP2861595B1 INCYTE CORP Substituted Tricyclic Compounds As Fgfr Inhibitors
Jun, 2033

(10 years from now)

EP2861595B9 INCYTE CORP Substituted Tricyclic Compounds As Fgfr Inhibitors
Jun, 2033

(10 years from now)

EP2861595A2 INCYTE CORP Substituted Tricyclic Compounds As Fgfr Inhibitors
Jun, 2033

(10 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10131667 INCYTE CORP Substituted tricyclic compounds as FGFR inhibitors Jun, 2033

(10 years from now)

Treatment: For the treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or other rearrangement

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
4.5MG TABLET;ORAL Prescription
9MG TABLET;ORAL Prescription
13.5MG TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.